Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Antihypertensive Drugs: Action of Calcium Channel Blockers

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thiazolidinedione-triazole hybrids: design, synthesis, and biological evaluation as dual inhibitors of α-amylase and aldose reductase with antioxidant activity for antidiabetic therapy.

Molecular diversity·2026

Same author

Discovery of thieno[2,3-<i>d</i>]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and <i>in vivo</i> validation in a breast cancer model.

RSC advances·2026

Same author

Retraction Note: Anti-inflammatory activity of novel derivatives of pyrazolo [3,4d] pyridazine against digestive system inflammation.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Same author

Cyclic-imide derivative (5e) attenuates hyperglycemia in type 1 diabetic rats by protecting pancreatic cells and enhancing insulin secretion.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2025

Same author

Synthesis and characterization of novel quinazolinone-based azo disperse dyes: molecular docking, ADMET, <i>in vitro</i>, and dyeing performance on polyester fabric.

RSC advances·2025

Same author

Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR/VEGFR-2 inhibition.

Bioorganic chemistry·2025

Search research articles

Related Experiment Video

Updated: May 23, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

Tadalafil.

Alaa A-M Abdel-Aziz¹, Yousif A Asiri, Adel S El-Azab

¹Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology

|April 4, 2012

Summary

Tadalafil, a new PDE5 inhibitor for erectile dysfunction (ED), offers a longer duration of action compared to sildenafil and vardenafil. Its unique chemical structure and properties are detailed.

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 23, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Pharmacology
Medicinal Chemistry

Background:

Erectile dysfunction (ED) is a common condition affecting many men.
Phosphodiesterase type 5 (PDE5) inhibitors are a primary treatment for ED.
Tadalafil represents a new therapeutic option in PDE5 inhibitor class.

Purpose of the Study:

To detail the pharmacological and chemical properties of tadalafil.
To compare tadalafil with existing PDE5 inhibitors like sildenafil and vardenafil.
To document analytical methods for tadalafil determination.

Main Methods:

Review of tadalafil's mechanism of action as a PDE5 inhibitor.
Comparison of chemical structures and PDE subtype selectivity.
Analysis of pharmacokinetic properties, including plasma residence time.
Documentation of physical properties and spectroscopic data.
Description of chromatographic methods for tadalafil analysis.

Main Results:

Tadalafil functions as a PDE5 inhibitor, similar to sildenafil and vardenafil.
Tadalafil exhibits distinct chemical structure and PDE subtype selectivity compared to sildenafil and vardenafil.
Tadalafil possesses a prolonged plasma residence time and therapeutic response window.
Physical properties, spectroscopic data, and analytical methods are documented.

Conclusions:

Tadalafil is a distinct PDE5 inhibitor with a favorable pharmacokinetic profile for ED treatment.
The documented properties and analytical methods support tadalafil's clinical use and further research.